What are Zevra Therapeutics, Inc.'s total assets?

Zevra Therapeutics, Inc. (ZVRA) holds $278.6M in total assets, up 61.3% year over year.

How much debt does Zevra Therapeutics, Inc. have?

Zevra Therapeutics, Inc. carries $1.1M in total debt against $205.8M of shareholders' equity, a debt-to-equity ratio of 0.01.

How much cash does Zevra Therapeutics, Inc. have?

Zevra Therapeutics, Inc. holds $95.6M in cash and equivalents.

Can Zevra Therapeutics, Inc. cover its short-term obligations?

Its current ratio is 4.89 — current assets exceed current liabilities.

Where does Zevra Therapeutics, Inc.'s balance sheet data come from?

Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Zevra Therapeutics, Inc. ZVRA Balance Sheet Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Cash and cash equivalents	$62.41M+84.7%	$33.79M-21.5%	$43.05M-34.2%	$65.47M-41.7%
Short-term investments	$128.61M+260%	$35.71M—	$0-100%	$481K—
Accounts receivable, net	$23.26M+121%	$10.51M-39.5%	$17.38M+109%	$8.3M+443%
Inventories	$13M-69.3%	$42.38M+269%	$11.49M+461%	$2.05M—
Raw materials	$7K-99.9%	$7.93M—	——	——
Work in process	$1.78M-45.4%	$3.26M—	——	——
Finished goods	$832K-53.3%	$1.78M—	——	——
Prepaid expenses and other current assets	$7M+72.7%	$4.05M+122%	$1.82M+8.1%	$1.69M+42.8%
Trading assets	——	——	——	——
Total current assets	$223.01M+159%	$86.03M-1.0%	$86.94M-6.4%	$92.83M-19.3%
Property and equipment, net	$489K+37.4%	$356K-51.6%	$736K-7.3%	$794K-10.2%
Operating lease right-of-use assets	13%-65,699,987%	65,700,000%-13,300,000%	79,000,000%-19,800,000%	98,800,000%-15,300,000%
Goodwill	$4.7M0.0%	$4.7M0.0%	$4.7M—	$0—
Intangible assets, net	$6.42M-90.7%	$68.99M-0.3%	$69.23M—	$0—
Other non-current assets	$143K-62.8%	$384K+309%	$94K-99.5%	$20M+3,982%
Total investment securities	$176.5M+323%	$41.7M—	——	——
Available-for-sale securities	$47.88M+697%	$6.01M—	$0—	$0-100%
Total assets	$284.73M+59.8%	$178.13M+3.4%	$172.33M+49.4%	$115.34M-13.2%
Accounts payable	$11.6M-54.4%	$25.46M-10.4%	$28.4M+360%	$6.17M+103%
Accrued expenses	$1.36M-39.7%	$2.26M-10.5%	$2.52M+251%	$719K-14.0%
Operating lease liabilities, current	$419K-0.2%	$420K-22.7%	$543K+13.1%	$480K+34.8%
Contract liabilities	$0—	$0—	——	——
Income taxes payable	$13.71M—	$0—	$0—	——
Total current liabilities	$39.28M+15.3%	$34.07M-53.8%	$73.72M+513%	$12.02M+184%
Long-term debt	$61.93M+4.1%	$59.5M+1,075%	$5.07M—	$0—
Operating lease liabilities, non-current	$859K+131%	$372K-18.4%	$456K-45.9%	$843K-31.6%
Operating Lease Liabilities (Total)	$1.28M+61.4%	$792K-20.7%	$999K-24.5%	$1.32M-16.7%
Other non-current liabilities	$1.71M-63.0%	$4.63M-37.9%	$7.46M+29,732%	$25K-19.4%
Total liabilities	$11.12M-92.0%	$138.46M+25.3%	$110.46M+175%	$40.22M+591%
Preferred stock	$0—	$0—	——	$0—
Common stock	$6K+20.0%	$5K+25.0%	$4K+33.3%	$3K-25.0%
Additional paid-in capital	$588.46M+6.0%	$555.3M+17.5%	$472.66M+8.3%	$436.27M+9.9%
Retained earnings	-$422.06M+16.5%	-$505.29M-26.4%	-$399.78M-13.0%	-$353.73M-32.5%
Accumulated other comprehensive income (loss)	-$764K-221%	$631K+1,567%	-$43K-138%	$113K—
Treasury stock	$10.98M0.0%	$10.98M0.0%	$10.98M+45.7%	$7.54M+168%
Total stockholders' equity	$154.66M+290%	$39.67M-35.9%	$61.86M-17.6%	$75.12M-26.1%
Total liabilities and stockholders' equity	$284.73M+59.8%	$178.13M+3.4%	$172.33M+49.4%	$115.34M-13.2%
Available-for-Sale Debt Securities - Amortized Cost	——	——	——	——
Allowance for Doubtful Accounts	$0—	$0—	——	——
Allowance for Doubtful Accounts Receivable (Current)	$0—	$0—	——	——
Total Cash, Cash Equivalents, and Restricted Cash (Inclusive)	$62.41M+84.7%	$33.79M-21.5%	$43.05M—	——
Available For Sale Securities Debt Securities Current	$128.61M+260%	$35.71M+44.6%	$24.69M+46.1%	$16.9M—
Deferred Tax Assets and Other Non-Current Assets	$143K-62.8%	$384K+309%	$94K+77.4%	$53K-87.9%
Finite-Lived Intangible Assets - Expected Amortization Expense (Year One)	——	——	——	——
Indefinite-Lived Intangible Assets	$2M0.0%	$2M—	——	——
Indefinite-Lived Intangible Assets, Gross	$2M0.0%	$2M—	——	——
Indefinite-Lived Research and Development Assets	$2M0.0%	$2M—	——	——
Indefinite-Lived Trademarks	$2M0.0%	$2M—	——	——
Investments - Amortized Cost Basis	——	——	——	——
Net Investment in Lease	$1.21M+84.5%	$657K-16.8%	$790K-20.0%	$988K-13.4%
Long-term marketable securities	$47.88M+697%	$6.01M—	$0—	$0-100%
Other intangible assets—net	$6.42M-90.7%	$68.99M-0.3%	$69.23M—	$0—
Operating lease right-of-use assets	$1.21M+84.5%	$657K-16.8%	$790K-20.0%	$988K-13.4%
Other non-current assets	$143K-62.8%	$384K+309%	$94K+77.4%	$53K-87.9%
Operating Lease Right-of-Use Assets in Other Assets	$1.21M+84.5%	$657K-16.8%	$790K-20.0%	$988K-13.4%
Software and Technology Licenses, Net	$143K-62.8%	$384K+309%	$94K+77.4%	$53K-87.9%
Accrued Contingent Liabilities	$0—	——	——	——
Accounts payable and other current liabilities (Note 11)	$11.6M-54.4%	$25.46M-10.4%	$28.4M+360%	$6.17M+103%
Accrued Income Taxes, Current	$13.71M—	$0—	——	——
Current portion of discount and rebate liabilities	$12.19M+144%	$4.99M+9.6%	$4.55M-2.3%	$4.66M—
Current portion of discount and rebate liabilities	$12.19M+106%	$5.93M—	——	——
Other accrued liabilities	$1.36M-39.7%	$2.26M-10.5%	$2.52M+251%	$719K-14.0%
Lease Liability Payments - 2020 (Remaining Three Months)	——	——	——	——
Operating Lease Liability Payments - 2024 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2025 (Lessee)	——	——	——	——
Lease Liability Payments - Due Year Two	——	——	——	——
Lease Liability Payments - Due Year Three	——	——	——	——
Lease Liability Payments - Remainder of Fiscal Year	——	——	——	——
Operating Lease Liability Payments Due	——	——	——	——
Operating Lease Liability - Undiscounted Excess Amount	——	——	——	——
Debt - Unamortized Discount (Premium) and Issuance Costs, Net	$925K-17.9%	$1.13M—	——	——
Operating Lease Liability Payments - 2026 (Lessee)	——	——	——	——
Operating Lease Liability Payments - 2027 (Lessee)	——	——	——	——
Total debt	$63.21M+4.8%	$60.3M+894%	$6.07M+356%	$1.33M-17.4%
Total Carrying Value of Debt	$63.61M+3.3%	$61.55M—	——	——
Common Stock Par Value Per Share	$0.000.0%	$0.00—	——	——
Common Stock Shares Issued	58.3M+5.6%	55.2M—	——	——
Convertible Preferred Stock Authorized Shares	10M0.0%	10M—	——	——
Convertible Preferred Stock Issued Shares	0—	0—	——	——
Convertible Preferred Stock Outstanding Shares	0—	0—	——	——
Additional paid-in capital	$588.46M+6.0%	$555.3M+17.5%	$472.66M+8.3%	$436.27M+9.9%
Preferred stock; $0.001 par value; 100 shares authorized; no shares issued and outstanding	$0—	$0—	——	$0—
Treasury Stock, Value	$10.98M0.0%	$10.98M0.0%	$10.98M+45.7%	$7.54M+168%
Preferred Stock Par Value Per Share	$0.000.0%	$0.00—	——	——
Shares Reserved for Future Issuance Under Stock Plans	18.4M-7.0%	19.8M—	——	——
Warrants and Rights Outstanding	——	——	——	——
Cumulative Cost Basis	——	——	——	——
Income taxes payable – long-term	$7.03M-51.3%	$14.43M—	$0—	——
Accounts Receivable, Allowance for Credit Loss	$0—	$0—	——	——
Total	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five	——	——	——	——
Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One	——	——	——	——
Cash and cash equivalents, end of period	$62.41M+84.7%	$33.79M-21.5%	$43.05M—	——
Class of Warrant or Right, Outstanding	——	——	——	——
Common stock, capital shares reserved for future issuance	$18.42M-7.0%	$19.8M—	——	——
Common stock, par value (in dollars per share)	$00.0%	$0—	——	——
Aggregate offering price	——	——	——	——
Common stock registered, shares (in shares)	——	——	——	——
Common stock, shares authorized (in shares)	$250M0.0%	$250M—	——	——
Common stock, shares issued (in shares)	$58.34M+5.6%	$55.25M—	——	——
Common Stock, Shares, Outstanding	$56.85M+5.9%	$53.67M—	——	——
Contract with Customer, Liability	$0—	$0—	——	——
Long-term debt, gross	$63.61M+3.3%	$61.55M—	——	——
Debt Instrument, Unamortized Discount (Premium), Net	$755K-18.0%	$921K—	——	——
Warrant liability	$9.58M-46.2%	$17.8M+10.6%	$16.1M+57.8%	$10.2M—
Variable rate debt, lower range of basis point spread	——	——	——	——
Discount and rebate liabilities, less current portion	$9.69M+26.6%	$7.66M-0.1%	$7.66M+77.1%	$4.33M—
Discount and rebate liabilities, less current portion	$9.69M+26.6%	$7.66M—	——	——
2028	——	——	——	——
2030	——	——	——	——
Remainder of 2026	——	——	——	——
2027	——	——	——	——
2029	——	——	——	——
Trademarks	$2M0.0%	$2M—	——	——
Raw materials	$7K-99.9%	$7.93M—	——	——
Investments Fair Value Disclosure	$176.5M+323%	$41.7M—	——	——
Lessee, operating lease, lease not yet commenced, liability, estimate to be paid, year one	——	——	——	——
Lessee, operating lease, lease not yet commenced, liability, to be paid, remainder of fiscal year	——	——	——	——
Lessee, operating lease, lease not yet commenced, liability, estimate to be paid, year two	——	——	——	——
Lessee Operating Lease Liability Payments Due	——	——	——	——
Lessee Operating Lease Liability Undiscounted Excess Amount	——	——	——	——
Loss Contingency Accrual	$0—	——	——	——
Operating Lease Weighted Average Discount Rate Percent	$0.13+31.3%	$0.1—	——	——
Preferred Stock, Par or Stated Value Per Share	$00.0%	$0—	——	——
Preferred Stock, Shares Authorized	$10M0.0%	$10M—	——	——
Preferred Stock, Shares Issued	$0—	$0—	——	——
Preferred Stock, Shares Outstanding	$0—	$0—	——	——
Warrant liability	$9.58M-46.2%	$17.8M—	——	——
Remainder of Fiscal Year 2024	——	——	——	——
Remainder of Fiscal Year 2025	——	——	——	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Zevra Therapeutics, Inc..

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Zevra Therapeutics, Inc.'s total assets?: Zevra Therapeutics, Inc. (ZVRA) holds $278.6M in total assets, up 61.3% year over year.
How much debt does Zevra Therapeutics, Inc. have?: Zevra Therapeutics, Inc. carries $1.1M in total debt against $205.8M of shareholders' equity, a debt-to-equity ratio of 0.01.
How much cash does Zevra Therapeutics, Inc. have?: Zevra Therapeutics, Inc. holds $95.6M in cash and equivalents.
Can Zevra Therapeutics, Inc. cover its short-term obligations?: Its current ratio is 4.89 — current assets exceed current liabilities.
Where does Zevra Therapeutics, Inc.'s balance sheet data come from?: Every line is extracted from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.